Novel C6-substituted 1,3,4-oxadiazinones as potential anti-cancer agents

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The insulin-like growth factor 1 receptor (IGF-1R) is a receptor tyrosine kinase frequently over-expressed in various cancers.
• Therapeutic resistance to existing IGF-1R inhibitors is a significant clinical challenge, often mediated by increased Src activation.
• There is a critical need for novel IGF-1R inhibitors capable of suppressing Src rephosphorylation.

Purpose of the Study:

• To identify novel small molecules targeting the IGF-1R signaling pathway.
• To develop inhibitors that can overcome resistance mechanisms associated with Src activation.
• To explore a new chemical scaffold structurally distinct from current tyrosine kinase inhibitors (TKIs).

Main Methods:

• Exploration of 2-aryl-1,3,4-oxadiazin-5-ones as a novel scaffold for inhibitor development.
• In vitro and in vivo evaluation of the compound LL-2003 in non-small cell lung cancer models.
• Assessment of IGF-1R and Src suppression, and induction of apoptosis.

Main Results:

• The compound LL-2003 demonstrated significant antitumor effects in vitro and in vivo.
• LL-2003 effectively suppressed both IGF-1R and Src phosphorylation.
• Apoptosis was induced in non-small cell lung cancer cells treated with LL-2003.

Conclusions:

• The novel 2-aryl-1,3,4-oxadiazin-5-one scaffold offers a promising strategy for developing new anticancer agents.
• LL-2003 represents a potential lead compound for overcoming resistance in IGF-1R-targeted therapies.
• This approach may open new avenues for more effective cancer treatments by targeting IGF-1R/Src signaling.